Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | Teknon Peritoneal Cancer Institute, Spain

9.90

Barcelona, Spain

Overview

Age group

Adults

Type of care

Inpatient

Method

Surgical

About the offer

Cytoreductive surgery is a type of surgery that removes as much cancerous tissue as possible. It is often done when cancer has grown into tumors or masses in the abdomen. After cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC) treatment involves giving high chemo doses directly to the peritoneal cavity. The name "hyperthermic" means that the chemotherapy is heated to a high temperature to make it work better at killing cancer cells. During the procedure, the patient is put to sleep, and a small cut is made in the abdomen. The surgeon takes out as much of the cancerous tissue as possible. The chemo drugs are heated to the right temperature and given to the peritoneal cavity. The chemotherapy is moved to the peritoneal cavity (usually around 90 minutes) for a certain amount of time. After that, the chemotherapy is drained out of the peritoneal cavity, and the cut is closed. This surgical method was developed by Dr. Paul Sugarbaker (USA) to remove all the peritoneal tumor deposits. The extent of surgery will depend on the number and distribution of the tumor deposits that the surgeons encounter. Due to the complexity of this surgery, it should only be performed by surgeons who are highly specialized and experienced in this procedure. Once the tumor deposits are surgically removed, the surgical team administers HIPEC ( heated intraperitoneal chemotherapy). During this part of the procedure, the abdomen is filled with heated chemotherapy solution and circulated with the help of a specialized device for 60-90 minutes, which is used to treat the microscopic residuals of the tumor and achieve a better result. Cytoreductive surgery and HIPEC removes a lot of cancerous tissue, which may not be possible with other types of treatment. High doses of chemo given directly to the tumor can kill cancer cells better than chemotherapy is shown all over the body. Patients may also live longer and have better quality of life. Types of cancers that can lead to peritoneal carcinomatosis and could benefit from Cytoreductive Surgery and HIPEC:Pseudomyxoma Peritonei (PMP)Appendix cancerOvarian cancerColorectal cancerMesotheliomaStomach cancerMany other types of cancer can cause carcinomatosis, such as endometrial cancer, small bowel cancer, hepatobiliary and pancreatic cancers, neuroendocrine tumors, and others.

What’s included

Medical service

Examination

clinical history-taking
medical records review
physical examination
consultation with an abdominal surgeon
consultation with an anesthesiologist
consultation with an oncologist
consultation with a dietitian and nutrition expert

Laboratory tests

complete blood count (CBC)
blood type test (ABO, Rh)
biochemical analysis of blood (kidney and liver function tests, thyroid function tests, electrolytes, glucose, lipid panel)
inflammation blood tests
coagulation studies
urinalysis

Diagnosis

ultrasound imaging of the abdomen
CT/MRI scan of the abdomen
histopathological specimen examination
electrocardiogram (ECG)
chest X-ray

Treatment

preoperative patient preparation
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy (HIPEC)
cost for any reoperation or complication management during hospitalization
postoperative care
symptomatic treatment

Other

cost of essential medicines
cost of essential materials
general anesthesia
hospitalization
stay in ICU
blood bank material
nursing service
discharge medical records
further recommendations

Distant service

follow-up consultations for the post-treatment period

Extra add-ons

Airport transfer

Single room

Companion hospitalization

Hospital meals

Personal coordinator

AiroCare

AiroMedical support

Payment protection

Patient advocacy

Price match

Meet the provider

Dr. Domenico Sabia

general surgery, peritoneal oncology, HIPEC and PIPAC surgery

9.90

Excellent

Why to choose us?

Specialized Peritoneal Cancer Institute

The Peritoneal Cancer Institute operates at the clinical base of the Teknon Medical Centre, one of the largest multidisciplinary hospitals in Spain, which allows the patient to receive any necessary medical care and provide the care and supervision needed in the postoperative period. The hospital regularly undergoes international certification and has been certified by Joint Commission International seven times, guaranteeing high quality and safety for medical services.

Experience in numbers

We are a high-volume dedicated center performing 3 Cytoreductive Surgeries with HIPEC procedures weekly. More than 170 patients per year receive advanced comprehensive cancer treatment, including cytoreductive surgery, HIPEC, PIPAC (pressurized intraperitoneal aerosolized chemotherapy), and systemic oncologic therapy.

Operation guaranty

Thanks to our massive experience, our team has developed a package covering all possible complication management procedures, including possible reoperation after HIPEC surgery. We know that many cases can be complicated due to the nature of the disease, and we ensure that patients can have adequate surgical management without additional fees.

Gallery

CIRUGÍA CITORREDUCTORA (CRS): COMPLICACIONES y RIESGOS — PERITONEAL CANCER INSTITUTE

ЦИТРЕДУКТИВНАЯ ОПЕРАЦИЯ (CRS): ОСЛОЖНЕНИЯ И РИСКИ — PERITONEAL CANCER INSTITUTE

CYTOREDUCTIVE SURGERY(CRS): COMPLICATIONS & RISKS — PERITONEAL CANCER INSTITUTE

Customize this offer

If you're not seeing exactly what you need here, send your custom request. You can discuss the content, specifics, price & timeline to create a personalized plan.

Location

Carrer de Vilana, 12, Sarrià-Sant Gervasi, 08022 Barcelona, Spain

FAQ

How effective is Cytoreductive Surgery with HIPEC?

Cytoreductive Surgery with HIPEC can cure patients, especially those with appendix cancer, PMP, some forms of mesothelioma, and ovarian cancer, even when there is a large amount of tumor in the abdomen at the time of diagnosis. For other tumors, such as colon cancer and gastric cancer, the CRS HIPEC treatment is applied when there is a more limited amount of tumor in the abdomen to achieve the best results. For all tumors that develop peritoneal metastasis, a chance for cure is only possible if surgery ( CRS HIPEC) can be included as part of the treatment.

Can HIPEC replace systemic chemotherapy?

In most cases, both HIPEC and systemic chemotherapy are required to achieve the best results. The methods are complementary and do not replace each other. Some kinds of tumors, such as PMP, do not benefit from systemic chemotherapy, and therefore, CRS and HIPEC are the only treatments patients receive.

What factors determine the indication for surgery and prognosis?

Many factors need to be evaluated before the decision to recommend CRS and HIPEC is made and also to determine the prognosis once surgery is done. The type of primary tumor ( such as appendix, colon, ovary, mesothelioma, etc. ) and the amount of the peritoneal metastasis that are present are some of the most important factors. The peritoneal carcinomatosis index (PCI) describes the number of tumors presents in the abdomen. Computed tomography (CT), MRI, and or diagnostic laparoscopy can be used to estimate the PCI before surgery, but the final assessment is done during surgery. The intraoperative PCI, as well as the CC score ( a description of the completeness of the surgical removal of the tumor), are essential to determine the prognosis after surgery.